Related Experiment Videos
Pulmonary dysfunction in pediatric oncology patients.
Sascha Meyer1, Harald Reinhard, Sven Gottschling
1Department of Pediatric Oncology, University Hospital of the Saarland, Kirrbergerstr. 66421 Homburg/Saar, Germany. sascha.meyer@uniklinik-saarland.de
Pediatric Hematology and Oncology
|May 27, 2004
Summary
Pediatric cancer patients face respiratory distress from cancer or treatments. This review covers causes like infections, chemotherapy lung injury, and bone marrow transplant complications.
Area of Science:
- Pediatric Oncology
- Pulmonology
- Hematology
Background:
- Children with cancer often experience respiratory issues, impacting pulmonary function.
- These issues can stem directly from the disease or as a side effect of treatments.
- Critical respiratory emergencies in pediatric cancer include airway obstruction and hyperleukocytosis syndrome.
Purpose of the Study:
- To review the primary causes of respiratory distress and lung injury in pediatric oncology and bone marrow transplant patients.
- To highlight infectious causes, treatment-related lung disease, and bone marrow transplant complications.
- To synthesize current literature on pulmonary dysfunction in this vulnerable population.
Main Methods:
- Literature review of relevant studies.
- Focus on pediatric oncology and bone marrow transplant patient populations.
- Emphasis on infectious, treatment-induced, and transplant-related pulmonary issues.
Main Results:
- Respiratory distress is a significant concern in pediatric cancer patients.
- Causes are multifactorial, including disease progression, infections, anti-neoplastic agents, and bone marrow transplant complications.
- Understanding these causes is crucial for timely intervention and management.
Conclusions:
- Respiratory complications are common and serious in pediatric cancer and bone marrow transplant recipients.
- A comprehensive understanding of diverse etiologies is essential for effective patient care.
- Further research and clinical vigilance are needed to mitigate pulmonary risks.